The in vitro activation of cyclophosphamide in the Hydra Developmental Toxicology Assay

• Published in: Fundamental and applied toxicology Vol. 15; no. 3; p. 488
• Main Authors: Newman, L M, Johnson, E M, Giacobbe, R L, Fu, L J
• Format: Journal Article
• Language: English
• Published: United States 01-10-1990
• Subjects: Animals; Biological Assay; Biotransformation; Cyclophosphamide - pharmacokinetics; Cyclophosphamide - toxicity; Hydra - drug effects; Hydra - growth & development; In Vitro Techniques; Microsomes, Liver - metabolism; Mixed Function Oxygenases - metabolism; Rats; Teratogens - pharmacokinetics
• ISSN: 0272-0590
• DOI: 10.1016/0272-0590(90)90035-I

The proteratogen cyclophosphamide (CP) was tested in the Hydra Assay in the presence and absence of an in vitro metabolic activation package (MAP) consisting of rat hepatic microsomes (0.06 nmol P450/ml), 500 microM NADPH, and 25 microM MgCl. This metabolic system was developed through a series of interrelated biochemical and biological assays to provide maximum cytochrome P450 mixed-function monooxygenase (MFO) metabolic capacity while controlling the inherent toxicity of the hepatic preparation and the attendant cofactors. Bioactivation of CP was confirmed under standard hydra assay conditions of pH 7.0 and 20 degrees C and compared with activation at 37 degrees C. Estimation of total metabolic capacity and verification of activation were made through the appearance of alkylating metabolites both in the absence and in the presence of hydra. Chemical exposure was maintained throughout the 92 +/- 2 hr assay with periodic renewal of media (and additives) at 4, 20, 28, 42, and 66 hr of incubation. Inclusion of bioactivation increased the toxicity of CP by two orders of magnitude. The minimal affective concentration in the adult and developmental portions of the assay was decreased from 4000 to 20 micrograms CP/ml and from 1000 to 4 micrograms CP/ml, respectively. By limiting the inherent toxicity of the MFO package, it was possible to avoid pulse-type exposures and ensure that all ontogenic stages were exposed to active metabolites. The addition of metabolic activation capacity to an in vitro assay, while not essential, markedly enhances its utility and breadth of application in developmental toxicity safety evaluations.